Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 2/2010

Open Access 01-06-2010

Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity

Authors: David G. DeNardo, Pauline Andreu, Lisa M. Coussens

Published in: Cancer and Metastasis Reviews | Issue 2/2010

Login to get access

Abstract

Tumor-associated myeloid cells have been implicated in regulating many of the “hallmarks of cancer” and thus fostering solid tumor development and metastasis. However, the same innate leukocytes also participate in anti-tumor immunity and restraint of malignant disease. While many factors regulate the propensity of myeloid cells to promote or repress cancerous growths, polarized adaptive immune responses by B and T lymphocytes have been identified as regulators of many aspects of myeloid cell biology by specifically regulating their functional capabilities. Here, we detail the diversity of heterogeneous B and T lymphocyte populations and their impacts on solid tumor development through their abilities to regulate myeloid cell function in solid tumors.
Literature
1.
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21(2), 137–148.CrossRefPubMed
2.
Ostrand-Rosenberg, S. (2008). Immune surveillance: a balance between protumor and antitumor immunity. Current Opinion in Genetics & Development, 18(1), 11–18.CrossRef
3.
Karin, M., Lawrence, T., & Nizet, V. (2006). Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell, 124(4), 823–835.CrossRefPubMed
4.
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nature Reviews Cancer, 6, 24–37.CrossRefPubMed
5.
Balkwill, F., Charles, K. A., & Mantovani, A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 7(3), 211–217.CrossRefPubMed
6.
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.CrossRefPubMed
7.
De Palma, M., & Coussens, L. M. (2008). Immune cells and inflammatory mediators as regulators of tumor angiogenesis. In W. D. Figg & J. Folkman (Eds.), Angiogenesis: An integrative approach from science to medicine (pp. 225–238). Springer: New York.
8.
Stout, R. D., & Bottomly, K. (1989). Antigen-specific activation of effector macrophages by IFN-gamma producing (TH1) T cell clones. Failure of IL-4-producing (TH2) T cell clones to activate effector function in macrophages. Journal of Immunology, 142(3), 760–765.
9.
Watkins, S. K., Egilmez, N. K., Suttles, J., & Stout, R. D. (2007). IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. Journal of Immunology, 178(3), 1357–1362.
10.
Wakabayashi, O., Yamazaki, K., Oizumi, S., Hommura, F., Kinoshita, I., Ogura, S., et al. (2003). CD4(+) T cells in cancer stroma, not CD8(+) T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Science, 94(11), 1003–1009.CrossRefPubMed
11.
Siddiqui, S. A., Frigola, X., Bonne-Annee, S., Mercader, M., Kuntz, S. M., Krambeck, A. E., et al. (2007). Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clinical Cancer Research, 13(7), 2075–2081.CrossRefPubMed
12.
DeNardo, D. G., Johansson, M., & Coussens, L. M. (2008). Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Reviews, 27(1), 11–18.CrossRefPubMed
13.
Ruffell, B., Denardo, D. G., Affara, N. I., & Coussens, L. M. (2010). Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine & Growth Factor Reviews, 21, 3–10.CrossRef
14.
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., et al. (2007). Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 450(7171), 903–907.CrossRefPubMed
15.
Girardi, M., Glusac, E., Filler, R. B., Roberts, S. J., Propperova, I., Lewis, J., et al. (2003). The distinct contributions of murine T cell receptor (TCR)gammadelta+ and TCRalphabeta+ T cells to different stages of chemically induced skin cancer. Journal of Experimental Medicine, 198(5), 747–755.CrossRefPubMed
16.
Girardi, M., Oppenheim, D., Glusac, E. J., Filler, R., Balmain, A., Tigelaar, R. E., et al. (2004). Characterizing the protective component of the alphabeta T cell response to transplantable squamous cell carcinoma. Journal of Investigative Dermatology, 122(3), 699–706.CrossRefPubMed
17.
Daniel, D., Chiu, C., Giraud, E., Inoue, M., Mizzen, L. A., Chu, N. R., et al. (2005). CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Research, 65, 2018–2025.CrossRefPubMed
18.
Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., & Hanahan, D. (2003). Immune enhancement of skin carcinogenesis by CD4+ T cells. Journal of Experimental Medicine, 197(8), 1017–1028.CrossRefPubMed
19.
Zhou, L., Chong, M. M., & Littman, D. R. (2009). Plasticity of CD4+ T cell lineage differentiation. Immunity, 30(5), 646–655.CrossRefPubMed
20.
Munk, M. E., & Emoto, M. (1995). Functions of T-cell subsets and cytokines in mycobacterial infections. European Respiratory Journal. Supplement, 20, 668s–675s.
21.
Romagnani, S., Parronchi, P., D'Elios, M. M., Romagnani, P., Annunziato, F., Piccinni, M. P., et al. (1997). An update on human Th1 and Th2 cells. International Archives of Allergy and Immunology, 113(1–3), 153–156.CrossRefPubMed
22.
Parker, D. C. (1993). T cell-dependent B cell activation. Annual Review of Immunology, 11, 331–360.PubMed
23.
Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews. Cancer, 4(1), 71–78.CrossRefPubMed
24.
Aspord, C., Pedroza-Gonzalez, A., Gallegos, M., Tindle, S., Burton, E. C., Su, D., et al. (2007). Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. Journal of Experimental Medicine, 204(5), 1037–1047.CrossRefPubMed
25.
DeNardo, D. G., Baretto, J. B., Andreu, P., Vasquez, L., Kolhatkar, N., Tawfik, D., et al. (2009). CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell, 16(2), 91–102.CrossRefPubMed
26.
Chin, Y., Janseens, J., Vandepitte, J., Vandenbrande, J., Opdebeek, L., & Raus, J. (1992). Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Research, 12(5), 1463–1466.PubMed
27.
Wilson, C. B., Rowell, E., & Sekimata, M. (2009). Epigenetic control of T-helper-cell differentiation. Nature Reviews. Immunology, 9(2), 91–105.CrossRefPubMed
28.
Weaver, C. T., Harrington, L. E., Mangan, P. R., Gavrieli, M., & Murphy, K. M. (2006). Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity, 24(6), 677–688.CrossRefPubMed
29.
Dong, C. (2008). TH17 cells in development: an updated view of their molecular identity and genetic programming. Nature Reviews. Immunology, 8(5), 337–348.CrossRefPubMed
30.
Ouyang, W., Kolls, J. K., & Zheng, Y. (2008). The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity, 28(4), 454–467.CrossRefPubMed
31.
Bettelli, E., Korn, T., Oukka, M., & Kuchroo, V. K. (2008). Induction and effector functions of T(H)17 cells. Nature, 453(7198), 1051–1057.CrossRefPubMed
32.
Wu, S., Rhee, K. J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H. R., et al. (2009). A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nature Medicine, 15(9), 1016–1022.CrossRefPubMed
33.
Miyahara, Y., Odunsi, K., Chen, W., Peng, G., Matsuzaki, J., & Wang, R. F. (2008). Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 105(40), 15505–15510.CrossRefPubMed
34.
Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., et al. (2008). Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clinical Cancer Research, 14(11), 3254–3261.CrossRefPubMed
35.
Zhang, J. P., Yan, J., Xu, J., Pang, X. H., Chen, M. S., Li, L., et al. (2009). Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. Journal of Hepatology, 50(5), 980–989.CrossRefPubMed
36.
Numasaki, M., Watanabe, M., Suzuki, T., Takahashi, H., Nakamura, A., McAllister, F., et al. (2005). IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. Journal of Immunology, 175(9), 6177–6189.
37.
Numasaki, M., Fukushi, J., Ono, M., Narula, S. K., Zavodny, P. J., Kudo, T., et al. (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101(7), 2620–2627.CrossRefPubMed
38.
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., et al. (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 31(5), 787–798.CrossRefPubMed
39.
Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., et al. (2006). High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 108(9), 2957–2964.CrossRefPubMed
40.
Hiraoka, N., Onozato, K., Kosuge, T., & Hirohashi, S. (2006). Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clinical Cancer Research, 12(18), 5423–5434.CrossRefPubMed
41.
Petersen, R. P., Campa, M. J., Sperlazza, J., Conlon, D., Joshi, M. B., Harpole, D. H., Jr., et al. (2006). Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer, 107(12), 2866–2872.CrossRefPubMed
42.
Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Menard, S., et al. (2009). FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology, 27(11), 1746–1752.CrossRefPubMed
43.
Trzonkowski, P., Szmit, E., Mysliwska, J., Dobyszuk, A., & Mysliwski, A. (2004). CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clinical Immunology, 112(3), 258–267.CrossRefPubMed
44.
Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T., & Whiteside, T. L. (2007). A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clinical Cancer Research, 13(15 Pt 1), 4345–4354.CrossRefPubMed
45.
Fehervari, Z., & Sakaguchi, S. (2004). CD4+ Tregs and immune control. Journal of Clinical Investigation, 114(9), 1209–1217.PubMed
46.
Feuerer, M., Hill, J. A., Mathis, D., & Benoist, C. (2009). Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nature Immunology, 10(7), 689–695.CrossRefPubMed
47.
Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms, D. R., et al. (2007). Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity, 27(4), 635–646.CrossRefPubMed
48.
Tang, Q., & Bluestone, J. A. (2008). The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nature Immunology, 9(3), 239–244.CrossRefPubMed
49.
Okamoto, R., Ueno, M., Yamada, Y., Takahashi, N., Sano, H., Suda, T., et al. (2005). Hematopoietic cells regulate the angiogenic switch during tumorigenesis. Blood, 105(7), 2757–2763.CrossRefPubMed
50.
De Palma, M., Venneri, M. A., Galli, R., Sergi Sergi, L., Politi, L. S., Sampaolesi, M., et al. (2005). Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell, 8(3), 211–226.CrossRefPubMed
51.
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., et al. (1999). Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes & Development, 13(11), 1382–1397.CrossRef
52.
Nozawa, H., Chiu, C., & Hanahan, D. (2006). Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12493–12498.CrossRefPubMed
53.
Takakura, N. (2006). Role of hematopoietic lineage cells as accessory components in blood vessel formation. Cancer Science, 97(7), 568–574.CrossRefPubMed
54.
Zou, W. (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews. Cancer, 5(4), 263–274.CrossRefPubMed
55.
Blankenstein, T. (2005). The role of tumor stroma in the interaction between tumor and immune system. Current Opinion in Immunology, 17(2), 180–186.CrossRefPubMed
56.
Bronte, V., Cingarlini, S., Marigo, I., De Santo, C., Gallina, G., Dolcetti, L., et al. (2006). Leukocyte infiltration in cancer creates an unfavorable environment for antitumor immune responses: a novel target for therapeutic intervention. Immunological Investigations, 35(3–4), 327–357.CrossRefPubMed
57.
Condeelis, J., & Pollard, J. W. (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell, 124(2), 263–266.CrossRefPubMed
58.
Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., et al. (2004). A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Research, 64(19), 7022–7029.CrossRefPubMed
59.
Lewis, C. E., & Pollard, J. W. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Research, 66(2), 605–612.CrossRefPubMed
60.
De Palma, M., & Naldini, L. (2006). Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. Biochimica et Biophysica Acta, 1766(1), 159–166.PubMed
61.
Coukos, G., Benencia, F., Buckanovich, R. J., & Conejo-Garcia, J. R. (2005). The role of dendritic cell precursors in tumour vasculogenesis. British Journal of Cancer, 92(7), 1182–1187.CrossRefPubMed
62.
Yang, L., Debusk, L. M., Fukuda, K., Fingleton, B., Green-Jarvis, B., Shyr, Y., et al. (2004). Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 6(4), 409–421.CrossRefPubMed
63.
Serafini, P., Borrello, I., & Bronte, V. (2006). Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Seminars in Cancer Biology, 16(1), 53–65.CrossRefPubMed
64.
Kisucka, J., Butterfield, C. E., Duda, D. G., Eichenberger, S. C., Saffaripour, S., Ware, J., et al. (2006). Platelets and platelet adhesion support angiogenesis while preventing excessive hemorrhage. Proceedings of the National Academy of Sciences of the United States of America, 103(4), 855–860.CrossRefPubMed
65.
Puxeddu, I., Alian, A., Piliponsky, A. M., Ribatti, D., Panet, A., & Levi-Schaffer, F. (2005). Human peripheral blood eosinophils induce angiogenesis. International Journal of Biochemistry & Cell Biology, 37(3), 628–636.CrossRef
66.
Takakura, N., Watanabe, T., Suenobu, S., Yamada, Y., Noda, T., Ito, Y., et al. (2000). A role for hematopoietic stem cells in promoting angiogenesis. Cell, 102(2), 199–209.CrossRefPubMed
67.
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., et al. (2008). “Re-educating” tumor-associated macrophages by targeting NF-kappaB. Journal of Experimental Medicine, 205(6), 1261–1268.CrossRefPubMed
68.
Qian, B., Deng, Y., Im, J. H., Muschel, R. J., Zou, Y., Li, J., et al. (2009). A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS One, 4(8), e6562.CrossRefPubMed
69.
Corthay, A., Skovseth, D. K., Lundin, K. U., Rosjo, E., Omholt, H., Hofgaard, P. O., et al. (2005). Primary antitumor immune response mediated by CD4+ T cells. Immunity, 22(3), 371–383.CrossRefPubMed
70.
Mantovani, A., Sica, A., & Locati, M. (2007). New vistas on macrophage differentiation and activation. European Journal of Immunology, 37(1), 14–16.CrossRefPubMed
71.
Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage activation. Nature Reviews. Immunology, 8(12), 958–969.CrossRefPubMed
72.
Wynn, T. A. (2004). Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Reviews. Immunology, 4(8), 583–594.CrossRefPubMed
73.
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., & Locati, M. (2004). The chemokine system in diverse forms of macrophage activation and polarization. Trends in Immunology, 25(12), 677–686.CrossRefPubMed
74.
Andreu, P., Johansson, M., Affara, N. I., Pucci, F., Tan, T., Junankar, S., et al. (2010). FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell, 17, 121–134.CrossRefPubMed
75.
Kapsenberg, M. L., & Kalinski, P. (1999). The concept of type 1 and type 2 antigen-presenting cells. Immunology Letters, 69(1), 5–6.CrossRefPubMed
76.
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., et al. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell, 16(3), 183–194.CrossRefPubMed
77.
Hagemann, T., Wilson, J., Burke, F., Kulbe, H., Li, N. F., Pluddemann, A., et al. (2006). Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. Journal of Immunology, 176(8), 5023–5032.
78.
Corthay, A. (2007). CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells. Advances in Experimental Medicine and Biology, 590, 195–208.CrossRefPubMed
79.
Newman, K. C., & Riley, E. M. (2007). Whatever turns you on: accessory-cell-dependent activation of NK cells by pathogens. Nature Reviews. Immunology, 7(4), 279–291.CrossRefPubMed
80.
Szekanecz, Z., & Koch, A. E. (2007). Macrophages and their products in rheumatoid arthritis. Current Opinion in Rheumatology, 19(3), 289–295.CrossRefPubMed
81.
Tiemessen, M. M., Jagger, A. L., Evans, H. G., van Herwijnen, M. J., John, S., & Taams, L. S. (2007). CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proceedings of the National Academy of Sciences of the United States of America, 104(49), 19446–19451.CrossRefPubMed
82.
Dilillo, D. J., Matsushita, T., & Tedder, T. F. (2010). B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Annals of the New York Academy of Sciences, 1183, 38–57.CrossRefPubMed
83.
Mizoguchi, A., & Bhan, A. K. (2006). A case for regulatory B cells. Journal of Immunology, 176(2), 705–710.
84.
Tan, T. T., & Coussens, L. M. (2007). Humoral immunity, inflammation and cancer. Current Opinion in Immunology, 19(2), 209–216.CrossRefPubMed
85.
Inoue, S., Leitner, W. W., Golding, B., & Scott, D. (2006). Inhibitory effects of B cells on antitumor immunity. Cancer Research, 66(15), 7741–7747.CrossRefPubMed
86.
Shah, S., Divekar, A. A., Hilchey, S. P., Cho, H. M., Newman, C. L., Shin, S. U., et al. (2005). Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. International Journal of Cancer, 117(4), 574–586.CrossRef
87.
Barbera-Guillem, E., Nelson, M. B., Barr, B., Nyhus, J. K., May, K. F., Jr., Feng, L., et al. (2000). B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunology and Immunotherapy, 48(10), 541–549.CrossRefPubMed
88.
Zapata, J. M., Llobet, D., Krajewska, M., Lefebvre, S., Kress, C. L., & Reed, J. C. (2009). Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood, 113(19), 4595–4603.CrossRefPubMed
89.
Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X., & Blankenstein, T. (1998). B cells inhibit induction of T cell-dependent tumor immunity. Nature Medicine, 4(5), 627–630.CrossRefPubMed
90.
Schreiber, H., Wu, T. H., Nachman, J., & Rowley, D. A. (2000). Immunological enhancement of primary tumor development and its prevention. Seminars in Cancer Biology, 10(5), 351–357.CrossRefPubMed
91.
Wijesuriya, R., Maruo, S., Zou, J. P., Ogawa, M., Umehara, K., Yamashita, M., et al. (1998). B cell-mediated down-regulation of IFN-gamma and IL-12 production induced during anti-tumor immune responses in the tumor-bearing state. International Immunology, 10(8), 1057–1065.CrossRefPubMed
92.
Barbera-Guillem, E., May, K. F., Jr., Nyhus, J. K., & Nelson, M. B. (1999). Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia, 1(5), 453–460.CrossRefPubMed
93.
Coussens, L. M., Hanahan, D., & Arbeit, J. M. (1996). Genetic predisposition and parameters of malignant progression in K14- HPV16 transgenic mice. American Journal of Pathology, 149(6), 1899–1917.PubMed
94.
Ammirante, M., Luo, J. L., Grivennikov, S., Dedospasov, S., & Karin, M. (2010). B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature, 464, 302–306.CrossRefPubMed
95.
96.
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30(7), 1073–1081.CrossRefPubMed
Metadata
Title
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
Authors
David G. DeNardo
Pauline Andreu
Lisa M. Coussens
Publication date
01-06-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9223-6

Other articles of this Issue 2/2010

Cancer and Metastasis Reviews 2/2010 Go to the issue

OriginalPaper

Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis

Acknowledgments

Biography—Alberto Mantovani, MD

OriginalPaper

Inflammation-mediated promotion of invasion and metastasis

OriginalPaper

TGFβ and cancer metastasis: an inflammation link

OriginalPaper

Bone marrow-derived mesenchymal stem cells and the tumor microenvironment

OriginalPaper

Why not treat human cancer with interleukin-1 blockade?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits